Category: Oncology

Bayer ASCO®20 Virtual Meeting Collection

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC) Abstract Poster Presentation Poster Authors: Karim Fizazi, Neal D. Shore, Teuvo Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Marie-Aude Le Berre, Oana Petrenciuc,…

Read the full article


Efficacia e sicurezza a lungo termine del trattamento di prima linea con ibrutinib per i pazienti con CLL/SLL: 5 anni di follow-up dallo studio RESONATE-2 di fase 3 Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study IMBRUVICA® (ibrutinib) capsule – Riassunto…

Read the full article

EMUC 2019 posters

Abiraterone in mCRPC. Posters presented at: 11th European Multidisciplinary Congress on Urological Cancers (EMUC19) PO5. Safety of abiraterone and enzalutamide in prostate cancer patients treated with anticoagulants C. Goena et al. Download PDF P042. A phase 2 study of the combination of PLK1 inhibitor, onvansertib, with abiraterone and prednisone in patients with metastatic castration-resistant prostate…

Read the full article